New gene biomarkers in joint disease from hemophilia patients
Official title: Individuazione di Nuovi Biomarker Nell'Artropatia Emofilica Attraverso Analisi Del Trascrittoma - Identification of New Biomarkers in Haemophilic Arthropathy Through Transcriptome Analysis
Run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07867821 · Data updated 2026-11-12
This study tests gene expression in blood and joint tissue from people with severe hemophilia who need joint surgery, to see how it compares with osteoarthritis and rheumatoid arthritis and with clinical features.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Academic / other |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | October 24, 2021 |
| Main results expected | March 1, 2027 |
| Study ends | May 1, 2027 |
| Registry record updated | October 9, 2026 |
| Trial ID | NCT07867821 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with severe hemophilia A or B who require therapeutic arthrocentesis, synovectomy, or orthopedic joint replacement for haemophilic arthropathy and can provide informed consent.
✕Probably not a fit
Patients who do not undergo joint surgery or do not meet the eligibility criteria may not benefit from the study findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study collects tissue samples from synovectomy and joint replacement surgeries and peripheral blood from patients with severe hemophilia A or B. Gene expression data will be analyzed and compared to data from patients with osteoarthritis and rheumatoid arthritis. Researchers will correlate gene expression with clinical, laboratory, inhibitor history, ultrasound, and histology findings to understand mechanisms of haemophilic arthropathy. The study builds on known joint damage from bleeds and investigates whether molecular profiles can inform future treatments. The primary endpoint is the relationship between gene expression patterns and patient phenotypes across arthritis types.
Why it matters
Potential benefit: If successful, the findings could help identify molecular targets to prevent or better treat haemophilic arthropathy.
How similar studies have gone: Previous work in related arthropathies has shown that gene-expression profiling can reveal disease mechanisms, but this specific approach in haemophilic arthropathy is exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of severe haemophilia A or B * The need to perform therapeutic arthrocentesis, surgical synovectomy or orthopaedic joint replacement surgery for haemophilic arthropathy in all potentially affected joints. * signed informed consent Exclusion Criteria: * Current presence of an inhibitor (anti-FVIII or anti-FIX); * Inability to give informed consent to participate in the study.
Where it's running
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy Recruiting
Study contacts
- Study coordinator: Roberta Gualtierotti, Principal Investigator
- Email: roberta.gualtierotti@unimi.it
- Phone: +390255034072
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Open Space vs Single Family Room NICU design and parental stress
This observational study will compare how Open Space and Single Family Room NICUs affect parental stress and involvement in care, as reported by parents and healthcare professionals.
-
Predicting unstable carotid plaques using radiomics and biomechanics
This study tests a noninvasive model to identify unstable carotid plaques in adults at initial diagnosis who may be candidates for carotid surgery.
-
How common is antimicrobial resistance in people with chronic lung diseases
This study will observe people with chronic lung diseases to see how often antimicrobial resistance appears in their respiratory samples and what factors are linked to higher resistance.
-
Personalized AML: Find biomarkers to predict response to venetoclax
This study tests whether single-cell analyses can help group AML patients by biology and find biomarkers that predict who will respond to venetoclax.
-
Cross immune links between breast cancer and thyroid autoimmunity and what it might mean for prognosis
This study tests whether women with both breast cancer and thyroid autoimmunity have different outcomes, by following patients identified through mammography and biopsy results.
-
Personalized Hemophilia Care Through Telemedicine and Adherence Monitoring
This study tests a telemedicine-based program to closely monitor bleeding, ensure patients stick to their treatment plan, and personalize care for adults with hemophilia who use a smartphone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.